IP Library › Granted Patent US 12,625,142
Granted Patent B2
US 12,625,142 · App. 18/011,916 · Granted May 12, 2026

Assay for measuring binding affinity for cardiolipin of biologically active compounds

Inventors: Pavels Arsenjans (Riga, LV); Pavels Dimitrijevs (Daugavpils, LV)
Assignee: Latvian Institute of Organic Synthesis
G01N33/582G01N33/683G01N33/92G01N2405/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,625,142
App. No.
18/011,916
Granted
May 12, 2026
Kind
B2
Abstract

The present invention relates to a method for the evaluation of binding affinity of biologically active substances for cardiolipin based on acridinium salt utilization as a fluorescent probe.

Claims (21)

1 . An assay method, comprising:

incubating a solution comprising a compound of interest, a lipid vesicle containing cardiolipin, and 3,6-di(azetidin-1-yl)-10-(3-(trimethylsilyl)propyl)acridin-10-ium iodide (I)

measuring fluorescence intensity at an excitation wavelength of 497 nm and at an emission wavelength of 529 nm, respectively.

2 . The method of claim 1 , wherein the compound of interest is an endogenous compound.

3 . The method of claim 1 , wherein the compound of interest comprises a metal cation.

4 . The method of claim 1 , wherein the compound of interest is an xenobiotic.

5 . The method of claim 1 , wherein the compound of interest comprises an ammonium or phosphonium cation.

6 . The method of claim 1 , wherein the compound of interest is an anthracycline or anthracenedione.

7 . The method of claim 1 , wherein the compound of interest is an aminoglycoside.

8 . The method of claim 1 , wherein the solution further comprises a buffer.

9 . The method of claim 1 , wherein 3,6-di(azetidin-1-yl)-10-(3-(trimethylsilyl)propyl)acridin-10-ium iodide is in a concentration of from 0.2 μM to 25 μM in the solution.

10 . The method of claim 1 , wherein the solution is incubated at 37° C.

11 . The method of claim 1 , further comprising determining an EC 50 value of the compound of interest after the measuring step.

12 . The method of claim 1 , wherein, before the incubating step, the method further comprises:

mixing the compound of interest and a lipid vesicle containing cardiolipin to form an intermediate solution;

incubating the intermediate solution; and

adding 3,6-di(azetidin-1-yl)-10-(3-(trimethylsilyl)propyl)acridin-10-ium iodide into the intermediate solution.

13 . A kit comprising:

3,6-di(azetidin-1-yl)-10-(3-(trimethylsilyl)propyl)acridin-10-ium iodide;

a buffer; and

a material containing cardiolipin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2026
From: LATVIAN INSTITUTE OF ORGANIC SYNTHESIS
To: NATIONAL INSTITUTE OF RESEARCH AND INNOVATION
Reel/Frame 075708/0308 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2023
From: ARSENJANS, PAVELS; DIMITRIJEVS, PAVELS
To: LATVIAN INSTITUTE OF ORGANIC SYNTHESIS
Reel/Frame 063472/0952 →
Priority Claims (1)
LV P2020000056 · Aug 20, 2020 · national
Continuity (1)
Related Publication 20230243840A1 · Aug 3, 2023
References Cited (13)
US 20230013542A1 · Arsenjans · 2023 [cited by examiner]
WO WO2021105780 · 2021 [cited by applicant]
WO WO2022038424 · 2022 [cited by applicant]
Dimitrijevs et al., “Cardiolipin in the spotlight: quantitative analysis and fluorescence-based competitive binding assay,” Sens. Actuators B, 2021, vol. 346, 130537, pp. 1-8. [cited by examiner]
International Search Report and Written Opinion in International Appln No. PCT/IB2020/058457, mailed on Dec. 9, 2020, 8 pages. [cited by applicant]
Kaewsuya et al., “Comparison of N-alkyl acridine orange dyes as fluorescence probes for the determination of cardiolipin,” Analytical Chimica Acta, Sep. 2008, 626(2):111-118. [cited by applicant]
Kaewsuya et al., “Fluorescent determination of cardiolipin using 10-N-nonyl acridine orange 11,” Analytical and Bioanalytical Chemistry, Feb. 2007, 387(8):2775-2782. [cited by applicant]
Mather et al., “Polycations induce the release of soluble intermembrane mitochondrial proteins,” Biochem Biophys Acta, Sep. 2000, 1503(2001):357-368. [cited by applicant]
Nicolay et al., “The Interaction of Adriamycin with Cardiolipin in Model and Rat Liver Mitochondrial Membranes,” Biochem Biophys Acta, Jun. 1984, 778(1984):359-371. [cited by applicant]
Parker et al., “Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers,” Biochem Biophys Acta, Jun. 2001, 1514(2):206-216. [cited by applicant]
Sautrey et al., “Negatively-charged Lipids as Potential Target for New Amphiphilic Aminoglycoside Antibiotics: a biophysical study,” J. Biological Chem., May 2016, M115.665364, 35 pages. [cited by applicant]
Sinibaldi et al., “Insights into Cytochrome c-Cardiolipin Interaction. Role Played by Ionic Strength,” Biochemistry, Apr. 2008, 47(2008):6928-6935. [cited by applicant]
Soussi et al., “H-n.m.r. evaluation of the ferricytochrome c-cardiolipin interaction,” Biochem. J., Aug. 1989, 265(1990):227-232. [cited by applicant]